Skip to main content
77°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Telix Pharmaceuticals Limited - American Depositary Shares
(NQ:
TLX
)
16.63
-0.73 (-4.21%)
Streaming Delayed Price
Updated: 10:46 AM EDT, Jun 6, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
June 03, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix to Host Investor Day in New York City on June 11, 2025
May 22, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
May 07, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
April 28, 2025
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Reports US$186M Q1 Revenue, Up 62% YOY
April 22, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
April 15, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Announces Cardinal Health for Gozellix Commercial Distribution
April 08, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Appoints Paul Schaffer as Chief Technology Officer
April 07, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Anne Whitaker Appointed as Non-Executive Director
April 03, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
April 01, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®
April 01, 2025
From
Telix ARTMS, Inc.
Via
GlobeNewswire
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
March 21, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
March 17, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Adds Lead-212 Isotope Production Capability
March 12, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
March 03, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
February 25, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
February 25, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
February 20, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
February 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Illuccix® Approved in the United Kingdom
February 12, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
January 30, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Completes Acquisition of RLS (USA) Inc.
January 27, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Illuccix® Receives European Approval
January 16, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
January 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
January 12, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
December 30, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
December 29, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
December 19, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
November 18, 2024
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
